利伐沙班联合氯吡格雷对房颤合并冠心病行PCI术患者的疗效和安全性观察

目的 研究利伐沙班联合氯吡格雷对心房颤动(房颤)合并冠心病行经皮冠状动脉介入治疗(PCI)术患者的疗效和安全性.方法 82例房颤合并冠心病行PCI术患者,根据随机数字表法分为对照组和研究组,每组41例.对照组患者术后给予华法林钠+氯吡格雷治疗,研究组患者术后给予利伐沙班+氯吡格雷治疗.比较两组出血性事件发生情况、治疗前...

Observation on the efficacy and safety of rivaroxaban combined with clopidogrel in patients with atrial fibrillation and coronary heart disease undergoing PCI

Objective To study the efficacy and safety of rivaroxaban combined with clopidogrel in patients with atrial fibrillation and coronary heart disease undergoing percutaneous coronary intervention(PCI).Methods A total of 82 patients with atrial fibrillation and coronary heart disease undergoing PCI were divided into the control group and the research group according to random numerical table,with 41 cases in each group.Patients in the control group were treated with warfarin sodium and clopidogrel postoperatively,and patients in the research group were treated with rivaroxaban and clopidogrel postoperatively.The occurrence of hemorrhagic events,cardiac function indexes before and after treatment,and occurrence of adverse cardiovascular and cerebrovascular events were compared between the two groups.Results There was no statistically significant difference in the incidence of major hemorrhage in thrombolysis in myocardial infarction(TIMI)and the global utilization of streptokinase and t-PA for occluded coronary arteries(GUSTO)bleeding classification between the two groups(P>0.05).After treatment,the left ventricular end diastolic diameter(LVEDD)(46.36±3.69)mm,left ventricular ejection fraction(LVEF)(56.64±1.87)%,early diastolic peak flow velocity of mitral valve/late diastolic peak flow velocity of mitral valve(E/A)(1.56±0.03)of the research group were better than(51.55±6.52)mm,(51.23±2.65)%,(1.11±0.03)of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse cardiovascular and cerebrovascular events 7.32%in the research group was lower than 24.39%in the control group,and the difference was statistically significant(P<0.05).Conclusion In patients who underwent PCI for atrial fibrillation combined with coronary artery disease,postoperative treatment with rivaroxaban and clopidogrel can improve the cardiac function and reduce the incidence of bleeding events in patients with a high safety profile during treatment,which is worth applying.